NicOx : Garufi ... e la Rivoluzione Pharma

Stato
Chiusa ad ulteriori risposte.
PiperJaffray apprécie> Auj. à 18:56
Nicox : De nouvelles données renforcent le potentiel du naproxcinod, PiperJaffray apprécie
Lundi 9 mars 2009 à 18:49 Imprimer






(Tradingsat.com) - PiperJaffray a réitéré lundi sa recommandation « Surperformance » et son objectif de cours de 15,8 euros sur NicOx. Le broker a relevé de précieuses informations en lisant le résumé de la présentation que doit faire le Dr. William B. White, Professeur de Médecine au Centre de Cardiologie de l' « University of Connecticut School of Medecine », Farmington, à l'ACC (American College of Cardiology) qui se tient à Orlando du 28 au 31 mars 2009.

Dans le résumé de cette présentation intitulée « The Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Lacks the Hypertensive Effects Seen With Naproxen in Patients With Osteoarthritis »), Piper Jaffray retient deux points clés.

Premièrement, 11,5% des patients hypertendus ont vu leur pression artérielle augmenter de plus de 10 millimètres de mercure avec le naproxcinod 750 mg, contre une proportion de 23,3% pour le naproxène 500 mg. Deuxièmement, la prise de naproxcinod engendre une perte du contrôle de la pression artérielle de patients arthrosiques hypertendus beaucoup moins fréquente que la prise de naproxène.

Deux constats importants dans la mesure où, comme le rappelle piperJaffray, le naproxène est pourtant déjà considéré comme le médicament anti-inflammatoire non stéroïdien dont les effets secondaires sont les moins gênants pour les personnes fragiles du cœur.

Le résumé de la présentation mentionne en particulier les patients qui utilisent un inhibiteur du système rénine-angiotensine pour contrôler leur hypertension. Dans ce dernier cas, la variation de la pression artérielle systolique s'est avérée en moyenne 6,5 millimètres de mercure plus importante avec le naproxène qu'avec le naproxcinod 750 mg (4,2 millimètres par rapport au naproxcinod 375 mg).

« Ce sont des différences cliniques hautement pertinentes, qui, de notre point de vue, renforcent le potentiel commercial du naproxcinod », estime PiperJaffray. Pour le broker, les différences indiquées sont en effet « tellement importantes que, si elles se répètent avec les trois essais de phase III, il deviendra difficile d'argumenter contre [l'existence d']un potentiel commercial significatif pour le médicament ».

Les données de cette présentation sont tirées de l'essais clinique 301, la première étude pivotale de phase 3 pour le naproxcinod. Deux autres ont suivi (302 et 303) dont les résultats ont été publiés l'année dernière. La société de biotechnologie a prévenu qu'elle communiquerait des données complémentaires de ces études au fur et à mesure des conférences scientifiques en 2009.
 
AGS / LES PREDATEURS DESABUSES Auj. à 18:50
NICOX : les prédicateurs « anti cox » risquent d’être désabusés
2009-03-09 | Actualités sociétés
A3Gadvise

Si Nicox « c’est de l’Intox », les prédicateurs de l’anti cox on toute les chances de se faire une « coxite » aigue lorsque les marchés prendront conscience du potentiel du Naproxcinod à comparer aux traitements anti-inflammatoires existants qui font grimper la pression artérielle. L’autre aspect créateur de richesse sera la finalisation des prétentions partenariales américaines. Le prochain congrès annuel de l'American College of Cardiology sera l’occasion d’apporter les précisions ultimes.

Comme indiqué dans notre commentaire du 5 mars dernier, force est de constater que la valeur tient bien le choc, et qu’une séquence spéculative devrait se remettre rapidement en place, dès le franchissement des 8 euros. Les prochaines séances seront très importantes à suivre. A la bourse de Paris, COX s’envole en fin de séance et termine en hausse de 6.44%, dans des volumes qui ne demandent qu’à se dynamiser.
 
si posto ce n'è il problema è che parte:lol::lol::lol::lol::lol::lol::lol::lol::lol:

doc prepara la brace............. :D i solitari faranno questa fine.... :sad:
non puoi scappare da solo alle fauci del kaimano........ :D:lol:

cinghiale-odalix2.jpg
 
AGS / LES PREDATEURS DESABUSES Auj. à 18:50
NICOX : les prédicateurs « anti cox » risquent d’être désabusés
2009-03-09 | Actualités sociétés
A3Gadvise

Si Nicox « c’est de l’Intox », les prédicateurs de l’anti cox on toute les chances de se faire une « coxite » aigue lorsque les marchés prendront conscience du potentiel du Naproxcinod à comparer aux traitements anti-inflammatoires existants qui font grimper la pression artérielle. L’autre aspect créateur de richesse sera la finalisation des prétentions partenariales américaines. Le prochain congrès annuel de l'American College of Cardiology sera l’occasion d’apporter les précisions ultimes.

Comme indiqué dans notre commentaire du 5 mars dernier, force est de constater que la valeur tient bien le choc, et qu’une séquence spéculative devrait se remettre rapidement en place, dès le franchissement des 8 euros. Les prochaines séances seront très importantes à suivre. A la bourse de Paris, COX s’envole en fin de séance et termine en hausse de 6.44%, dans des volumes qui ne demandent qu’à se dynamiser.

eccoli gli jettatori............ :down::down: :D sono ovunque............ :wall::wall::D presto le vaschette si riempiranno in abbondanza!!!! :cool:

mm_Foto_Selezione Italiana_pr cotto.jpg
 
E VIC avrà shortato!!!!!!!!!!! forse è meglio che si ricopra in fretta <<<<<meglio prestargli un mezzo di locomozione


motocesso-B.jpg
motocesso-B.jpg
a meno che non abbia fatto una brutta fine
moto-autobus3-B.jpg
moto-autobus3-B.jpg
 
LONDON, March 9 (Reuters) - European drugmakers may sit out this dance.

U.S. Merck & Co Inc's move to buy Schering-Plough Corp for $41 billion just six weeks after Pfizer Inc's $68 billion purchase of Wyeth signals a new round of consolidation in the global industry.

For now though, European giants like GlaxoSmithKline Plc , Novartis AG, and Sanofi-Aventis SA show no sign of joining in -- notwithstanding that all three were themselves created by such mega-mergers.

'U.S. consolidation is technically easier to do,' Jeffrey Holford of stockbroker Jefferies said. 'In Europe, it is a lot more difficult and we don't see the same degree of consolidation, if any.'

Any cross-border bid consisting largely of foreign shares would be risky as investors in the target company may not want to hold onto them and could sell them back into the market, creating a so-called flowback problem.

The problems of slowing drug sales, looming patent expiries and sliding prices, as politicians ratchet up pressure on the industry, are the same on both sides of the Atlantic.

But leaders of Europe's big drugmakers have been vocal in airing doubts about large-scale deals since Pfizer shocked the industry with its move on Wyeth in January.

They say mega-mergers may bring a short-term earnings boost, but do not usually fix the long-term issue of inadequate pipelines of new drugs.

Andrew Witty, chief executive of Glaxo, the world's second largest drugmaker by sales after Pfizer, has said he is not interested in large-scale M&A.

Novartis CEO Daniel Vasella also said he has no further plans for big transactions because Novartis was committed to buying U.S. eyecare group Alcon.

Sanofi's new CEO Chris Viehbacher does not rule out a big deal completely but made clear last week it was not on his agenda for now.

Instead, Viehbacher will focus on deals below $15 billion.

Roche, meanwhile, said it was not interested in mega-mergers and is pre-occupied with its planned $46 billion buyout of minorities in Genentech -- a deal which may be 'mega' in cash terms but which Mirabaud Securities analyst Nick Turner says actually resembles a share buyback.

'As far as European consolidation goes, we see any deals as unlikely,' said Simon Mather, an analyst with WestLB.

ASLEEP AT THE WHEEL?

Not everyone is convinced the Europeans have got it right.

'The Europeans are asleep at the wheel -- they need to react to this. They cannot allow the U.S. peer group to consolidate and effectively take market share away from them,' said Navid Malik, an analyst at Matrix Corporate Capital.

Market share is important because drugmakers need dominance in their selected therapeutic areas so they can better pitch for business with insurance companies and governments.

Both the Merck/Schering and Pfizer/Wyeth deals were driven by a desire to cut costs and take capacity out of an over-supplied industry.

Similar overcapacity also exist among European companies, with AstraZeneca Plc and Sanofi the most obvious examples, according to UBS analyst Gbola Amusa.

'Sanofi and AstraZeneca still have a lot of excess capacity and I would expect that at some stage in the future we would see somewhat sizeable deals from both of them,' he said.

But investors hoping AstraZeneca -- a perennial rumoured takeover target -- will be sold at a juicy premium may be disappointed as long as uncertainty remains over patent protection for its key cholesterol drug Crestor.

'Any CEO who bought AstraZeneca and later lost Crestor in 2010 would also probably lose their job, and that is enough of a poison pill to prevent Astra from being bought,' Amusa said.

Instead, he saw AstraZeneca itself moving to do an acquisition, with mid-sized specialty drugmaker Shire Plc a possible target.

One obvious takeover candidate left on the shelf by the latest deal-making is Bristol-Myers Squibb Co, probably the subject of more takeover rumours in recent years than any other drug company.

It has deals with both AstraZeneca, on two experimental diabetes drugs, and Sanofi, on blood thinner Plavix. But it could well prove too big a bite for similar-sized AstraZeneca, while Sanofi has made clear its partnership is sufficient for now
 
March 09, 2009: 01:23 PM ET


Johnson & Johnson (JNJ) could throw a wrench in Merck & Co.'s (MRK) plans to buy Schering-Plough Corp. (SGP) for $41 billion, potentially making the acquistion less lucrative or even disrupting it completely.

The potential discord centers on the blockbuster anti-inflammatory drug Remicade, which J&J and Schering-Plough co-market. J&J handles U.S. marketing, and Schering sells it outside the U.S. The agreement, which dates to the 1990s, also covers a new drug, golimumab, expected to go on sale later this year.

As part of the partnership, J&J has the opportunity to acquire full rights to the drugs if Schering-Plough were to be taken over, a so-called "change-in- control" provision, according to analysts.

Remicade generated $2.1 billion in sales for Schering-Plough last year, making it an attractive part of the acquisition for Merck, which has seen slowdowns in sales growth for its top products recently. J&J recorded $3.7 billion in Remicade sales.

Merck, of Whitehouse Station, N.J., and Kenilworth, N.J.-based Schering- Plough, however, are trying to sidestep the J&J rights and allow Merck to inherit Schering's rights to the drugs following the acquisition.

They have structured the $41 billion cash-and-stock takeover as a "reverse merger," under which Schering-Plough would technically be the surviving corporation, even though it would have Merck's name and be controlled by Merck shareholders and management. The merged entity would have a board of directors that consists of about 15 Merck directors and three Schering directors - but technically it would be Schering's board making these changes.

By taking these steps, Merck executives say the acquisition of Schering-Plough won't trigger the change-of-control provision in the J&J/Schering marketing agreement for Remicade and golimumab.

"Under the expressed terms of the distribution agreement, this change of control provision focuses on whether there has been a change in the surviving public company," Merck General Counsel Bruce Kuhlik told analysts on a conference call. "It doesn't refer to a stock ownership or anything of the sort."

Of course, J&J might feel differently, though a spokesman for the New Brunswick, N.J., company declined to comment on the matter Monday.

If J&J claims the change-of-control provision is triggered, the dispute would go to mandatory arbitration, Kuhlik said.

Merck and Schering-Plough executives tried not to take a combative stance, saying they planned to work with J&J on the matter. Schering-Plough Chief Executive Officer Fred Hassan said he had a phone conversation with J&J CEO William Weldon Monday morning, which he said was cordial.

But Kuhlik also said Merck will defend its rights, if necessary.

Also, Merck executives played down the importance of holding onto Remicade and golimumab. CEO Richard Clark said "this is a strategic bid for the future and it's not based on one or two products." Chief Financial Officer Peter Kellogg said Merck's post-acquisition earnings forecast would still hold up regardless of how the J&J/Schering matter plays out. Merck predicts high single-digit average annual earnings growth from 2009-13, excluding restructuring costs and other items.

Sanford Bernstein analyst Tim Anderson said one possible outcome is "horse trading" that results in Merck retaining rights to Remicade and golimumab. He also raised possibility of J&J making a rival bid for Schering, saying the companies would make a good fit.

Schering-Plough isn't the only party to Monday's deal that has a relationship with J&J. Merck has a joint venture with J&J to market non-prescription medicines such as Pepcid.
 
Stato
Chiusa ad ulteriori risposte.

Users who are viewing this thread

Back
Alto